View ValuationTong Ren Tang Technologies 향후 성장Future 기준 점검 1/6Tong Ren Tang Technologies (는) 각각 연간 12.4% 및 7.8% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 12.2% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.1% 로 예상됩니다.핵심 정보12.4%이익 성장률12.25%EPS 성장률Pharmaceuticals 이익 성장14.8%매출 성장률7.8%향후 자기자본이익률7.10%애널리스트 커버리지Low마지막 업데이트29 Apr 2026최근 향후 성장 업데이트공시 • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.모든 업데이트 보기Recent updates공시 • Apr 27+ 1 more updateTong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026, at 10:00 China Standard Time. Location: no. 28 tiangui avenue, daxing district, beijing China공시 • Mar 16Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026공시 • Feb 06Tong Ren Tang Technologies Co. Ltd. Announces Appointment of Mr. Siu, Paul Yu Hay as Independent Non-Executive Director and Changes in Board Committee Composition, Effective February 6, 2026Tong Ren Tang Technologies Co. Ltd. announced that, following the extraordinary general meeting held on February 6, 2026, announced that, with effect from 6 February 2026, Mr. Siu, Paul Yu Hay has been appointed as an independent non-executive Director of the ninth session of the Board. The resignation of Mr. Li Siu Bun as an independent non-executive Director has also taken effect from the same date. Mr. Siu, Paul Yu Hay will enter into a director's service contract with the Company for a term commencing from the date of his appointment (i.e. 6 February 2026) and until the end of this session of the Board, subject to re-election at the end of the term. The resignation of Mr. Li Siu Bun as the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Strategy and Planning Committee has also taken effect on 6 February 2026. The Board further resolved on 6 February 2026 to appoint Mr. Siu, Paul Yu Hay as the chairman of the Audit Committee, and a member of the Remuneration Committee and the Strategy and Planning Committee, all with effect from the same date.공시 • Jan 14Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Li Siu Bun from the Positions as an Independent Non-Executive Director, Chairman of the Audit Committee of the Board and A Member of Each of the Remuneration Committee of the Board and the Strategy and Planning CommitteeOn 13 January 2026, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Li Siu Bun, informing the Board of his resignation from the positions as an independent non-executive Director, chairman of the audit committee of the Board and a member of each of the remuneration committee of the Board and the strategy and planning committee of the Board due to work adjustments. The aforesaid resignation of Mr. Li will take effect upon the new independent non-executive Director being elected by the shareholders of the Company at the general meeting to be held in due course.공시 • Dec 31Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. held an extraordinary general meeting on December 30, 2025, at which the appointment of Ms. Du Xin as a non-executive Director of the ninth session of the Board of the Company was approved and confirmed. The resignation of Mr. Chen Fei as a non-executive Director has also taken effect from the same date. Ms. Du Xin will enter into a director’s service contract with the Company for a term commencing from the date of her appointment, December 30, 2025, and until the end of this session of the Board, subject to re-election at the end of the term. Ms. Du Xin’s remuneration for her services as a non-executive Director is nil, which is determined by the Board with reference to the recommendation from the remuneration committee of the Board, having taken into account her duties and responsibilities with the Company and the prevailing market conditions. As at the date of this announcement, Ms. Du Xin’s biographical details remain unchanged from those stated in the circular dated December 1, 2025 save as disclosed in this announcement. As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza, Mr. Zhan Yuan Jing and Mr. Li Siu Bun as independent non-executive Directors, and Mr. Zhu Dong Sheng as employee Director.공시 • Nov 28+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Executive Changes, Effective November 28, 2025The board of directors (the "Board") of Tong Ren Tang Technologies Co. Ltd. (the "Company") hereby announces that, with effect from 28 November 2025, (i) Mr. Li Yijun ("Mr. Li") has resigned as the company secretary of the Company, the secretary of the Board, and the authorised representative (the "Authorised Representative") under the Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") of the Company due to his family reasons; and (ii) Ms. Yung Mei Yee ("Ms. Yung") has ceased to serve as the agent for acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") due to work adjustment. Both Mr. Li and Ms. Yung have confirmed that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board also announced that, with effect from 28 November 2025, (i) Ms. Ma Wing Yee ("Ms. Ma") has been appointed as the company secretary of the Company, the Authorised Representative and the Process Agent; and (ii) Mr. Han Guan Zhao ("Mr. Han") has been appointed as the secretary of the Board. Ms. Ma is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 10 years of experience in corporate governance and company secretarial practice in listed companies on the Stock Exchange. She is currently the company secretary or joint company secretary of a few listed companies on the Stock Exchange. Ms. Ma obtained a bachelor's degree in Arts from the University of Hong Kong. She is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Han, aged 46, is a corporate legal adviser with a postgraduate qualification. He formerly served as the office senior legal affairs manager and manager of the legal affairs department of COFCO Feed Co. Ltd. Mr. Han joined the Company in December 2019, he currently serves as deputy general manager, general legal counsel and chief compliance officer of the Company.공시 • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2025 Results on Aug 26, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2025 results on Aug 26, 2025공시 • Jun 12+ 1 more updateTong Ren Tang Technologies Co. Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on 11 August 2025Tong Ren Tang Technologies Co. Ltd. announced at annual general meeting held on June 12, 2025, the shareholders approved the proposal of payment of a final dividend of RMB 0.18 (equivalent to HKD 0.196600) (tax inclusive) per share for the year ended 31 December 2024, will be paid on 11 August 2025 to the Shareholders whose names appear on the registers of members of the Company on 23 June 2025.공시 • May 20Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025, at 13:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, beijing, prc., China공시 • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025공시 • Oct 29Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Yung Mei Yee as Joint Company SecretaryThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that, due to work adjustment, Ms. Yung Mei Yee ("Ms. Yung") has resigned as the joint company secretary of the Company with effect from 29 October 2024. Ms. Yung has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Following the resignation of Ms. Yung, Mr. Li Yijun, the other Joint Company Secretary, who possess the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company with effect from 29 October 2024.공시 • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2024 Results on Aug 30, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2024 results on Aug 30, 2024공시 • Jun 13+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Payment of Final Dividend for the Year Ended 31 December 2023, Payable on 09 August 2024Tong Ren Tang Technologies Co. Ltd. announced that at its AGM held on June 12, 2024, To consider and, if thought fit, to approve the proposal of payment of a final dividend of RMB 0.18 (tax inclusive) per share for the year ended 31 December 2023. Ex-dividend date is 14 June 2024. Record date is 23 June 2024. Payment date is 09 August 2024.공시 • May 22Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024, at 09:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, the prc, beijing China공시 • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024공시 • Mar 05Tong Ren Tang Technologies Co. Ltd. Receives Notice of Approval for Clinical Trial of MedicineTong Ren Tang Technologies Co. Ltd. announced that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (Yao Wu Lin Chuang Shi Yan Pi Zhun Tong Zhi Shu) issued by the National Medical Products Administration. Details are as follows: Basic information of the medicine: Qishen Granules (Qi Can Ke Li) Applicant: Tong Ren Tang Technologies Co. Ltd.'s Pharmaceutical Factory. Category of registration: Registration category 1.1 of traditional Chinese medicines. Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication. Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis. Acceptance number: CXZL2300074. Notice number: 2024LP00491. Review conclusion: According to the Drug Administration Law of the People's Republic of China (<Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) /V Vaccine Administration Law of the People'sRepublic of China (Zhong Hua Ren Minong He Guo Yi Miao Guan Li Fa >) and relevant regulations, Qishen Granules (Qi Can Ke Li) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction. Research and development of the medicine and related information. The Qishen Granules ("Qi Can Ke Li") applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and bloodstasis. As at the date of this announcement, the Company has invested approximately RMB 7.8 million (unaudited) in the research and development of Qi Can Ke Li). Risk warning: In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors. There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.공시 • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.공시 • Jan 22Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of Tong Ren Tang Technologies Co. Ltd. announce that the extraordinary general meeting of the Company was held on 22 January 2024, approved the appointment of Mr. Di Shu Bing as an executive Director of the eighth session of the Board. Following the resignation of Mr. Gu Hai Ou as an executive Director, Mr. Di Shu Bing has been appointed as an executive Director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Mr. Di Shu Bing commence from the date of appointment (i.e. 22 January 2024) and until the end of this session of the Board, subject to re-elected at the end of the term. Mr. Di Shu Bing will not receive remuneration for his service as an executive Director. The Board announce that the Board resolved on 22 January 2024 to elect Mr. Di Shu Bing as the Chairman of the Board. On the same day, the Board also resolved to appoint Mr. Di Shu Bing as the chairman of the nomination committee of the Board and the chairman of the strategy and planning committee of the Board. The Board hereby announces that, Mr. Di Shu Bing was appointed as an authorized representative of the Company under the Rule 3.05 of the Hong Kong Listing Rules with effect from 22 January 2024.공시 • Dec 13Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Gu Hai Ou as Executive Director, Chairman of the Board, Chairman of the Nomination Committee, Chairman of the Strategy and Planning CommitteeOn 13 December 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Gu Hai Ou ("Mr. Gu"), informing the Board of his resignation from the positions as an executive Director, chairman of the Board, chairman of the nomination committee of the Board, chairman of the strategy and planning committee of the Board and the authorized representative, due to work adjustments. The above-mentioned resignation of Mr. Gu will take effect upon the new executive Director being elected by the shareholders of the Company (the "Shareholders") at the general meeting to be held. Mr. Gu has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the Shareholders. The Board further announces on 13 December 2023, proposal in relation to the appointment of Mr. Di Shu Bing ("Mr. Di") as the executive Director of the eighth Board of Directors of the Company, and to have the Board recommend his remuneration and authorize the Board to enter into a service contract with him. The Board therefore proposed to appoint Mr. Di as an executive Director in accordance with relevant laws and regulations and the articles of association of the Company. The proposed appointment of Mr. Di as an executive Director is subject to the approval by the Shareholders at the general meeting. Mr. Di Shu Bing (), aged 49, a senior accountant with a master degree of public administration. Mr. Di previously served as the finance supervisor of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, the deputy manager of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, a member of the Party Committee and the deputy general manager of Beijing Tong Ren Tang Commercial Investment Group, the assistant to the general manager and head of economic operation department of China Beijing Tong Ren Tang Group Co. Ltd., a director of Beijing Tong Ren Tang Health Industry Investment Co. Ltd., the chairman of Beijing Tong Ren Tang Traditional Chinese Medicine Formula Granules Investment Co. Ltd., a director of Beijing Tong Ren Tang Biological Product Development Co. Ltd., a director of Beijing Tong Ren Tang Cosmetics Co. Ltd., the vice chairman of Beijing Entrepreneurs Association and the vice chairman of Beijing Enterprise Confederation, the deputy head of the finance department, the deputy head and head of the investment management department, the secretary of the Party Committee, a director and the general manager of Beijing Tong Ren Tang Company Limited. Mr. Di currently serves as party secretary of the CPC Committee and chairman of Beijing Tong Ren Tang Company Limited, the deputy general manager of China Beijing Tong Ren Tang Group Co. Ltd. and the vice chairman of Beijing Pharmaceutical Profession Association.공시 • Aug 26Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. announced following the resignation of Mr. Wang Yu Wei as an executive director, Mr. Chen Jia Fu has been appointed as an executive director of the eighth session of the board of the company as approved by the Shareholders at the EGM. The terms of office of Mr. Chen Jia Fu commence from the date of appointment (that is 25 August 2023) and until the end of this session of the board, subject to re-elected at the end of the term. Mr. Chen Jia Fu will not receive remuneration for his service as an executive director. Change in board committee members: The board further announced that following the resignation of Mr. Wang Yu Wei as an executive Director, Mr. Chen Jia Fu has been appointed as a member of the strategy and planning committee of the board with effect from 25 August 2023.공시 • Aug 04Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2023 Results on Aug 24, 2023Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2023 results on Aug 24, 2023공시 • Jun 16+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Board ChangesOn 15 June 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Wang Yu Wei, informing the Board of Mr. Wang's application for resignation from the position as an executive Director and the general manager of the Company due to work changes. The resignation of Mr. Wang as an executive Director will take effect upon the new executive Director being elected by the shareholders of the Company at the general meeting to be held and his resignation as the General Manager has taken effect from 15 June 2023. The Board further announced that, on 15 June 2023, the Board proposed to appoint Mr. Chen Jia Fu as an executive Director and the General Manager. The proposed appointment of Mr. Chen as an executive Director is subject to the approval by the Shareholders at the general meeting. The proposed appointment of Mr. Chen as the General Manager has taken effect from 15 June 2023. Mr. Chen Jia Fu, aged 54, a pharmacist-in-charge and a licensed pharmacist with a postgraduate degree. He formerly served as the deputy secretary to the Party Committee of the Company, the secretary to the Disciplinary Inspection Committee of the Company, the chairman of the labour committee of the Company, and the deputy general manager of the Company. He used to work as the deputy general manager of Beijing Tong Ren Tang Company Limited and used to work as the chairman of the board, the secretary of general Party branch, the director and the general manager of Beijing Tong Ren Tang Pharmaceutical Co. Ltd. He currently serves as the secretary of the Party Committee of the Company and the General Manager.공시 • Feb 17Tong Ren Tang Technologies Co. Ltd. Announces Change of DirectorThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that the extraordinary general meeting (the "EGM") of the Company was held at No. 20 Nansanhuan Zhonglu, Fengtai District, Beijing, the People's Republic of China (the "PRC") at 9:30 a.m., on 16 February 2023 approve the appointment of Ms. Wang Chun Rui as a non-executive Director of the eighth session of the Board of the Company and the remuneration proposed by the Board, and to authorize the Board to enter into the service contract with Ms. Wang Chun Rui. Following the resignation of Ms. Guo Ya Qing as a non-executive director, Ms. Wang Chun Rui has been appointed as a non-executive director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Ms. Wang Chun Rui commence from the date of appointment (i.e. 16 February 2023) and until the end of this session of the Board, subject to re-elected at the end of the term. Ms. Wang Chun Rui will not receive remuneration for her service as a non-executive Director.이익 및 매출 성장 예측OTCPK:TGRN.F - 애널리스트 향후 추정치 및 과거 재무 데이터 (CNY Millions)날짜매출이익자유현금흐름영업현금흐름평균 애널리스트 수12/31/20288,224580N/A690112/31/20277,563514N/A640212/31/20266,982455N/A933212/31/20256,4843961,4461,562N/A9/30/20256,7164141,4441,576N/A6/30/20256,9484321,4431,589N/A3/31/20257,104477642802N/A12/31/20247,260522-15916N/A9/30/20247,068586-516-366N/A6/30/20246,877651-873-747N/A3/31/20246,825620-211-97N/A12/31/20236,773590451554N/A9/30/20236,849611667797N/A6/30/20236,9246338841,041N/A3/31/20236,458608722882N/A12/31/20225,992583560724N/A9/30/20225,820546761909N/A6/30/20225,6495109621,095N/A3/31/20225,5255099191,064N/A12/31/20215,4005078771,033N/A9/30/20215,267509498793N/A6/30/20215,133511120552N/A3/31/20214,870489-103494N/A12/31/20204,607468-325436N/A9/30/20204,425387-1626N/A6/30/20204,242307323816N/A3/31/20204,359362553934N/A12/31/20194,4764187831,052N/A9/30/20194,604523N/A1,120N/A6/30/20194,731628N/A1,187N/A3/31/20194,895653N/A1,086N/A12/31/20185,060678N/A985N/A9/30/20185,054681N/A843N/A6/30/20185,047683N/A700N/A3/31/20185,036675N/A690N/A12/31/20175,025667N/A680N/A9/30/20174,882624N/A569N/A6/30/20174,739582N/A459N/A3/31/20174,702589N/A434N/A12/31/20164,665596N/A410N/A9/30/20164,546603N/A396N/A6/30/20164,426610N/A383N/A3/31/20164,247575N/A343N/A12/31/20154,067541N/A304N/A9/30/20153,915529N/A357N/A6/30/20153,764517N/A411N/A더 보기애널리스트 향후 성장 전망수입 대 저축률: TGRN.F 의 연간 예상 수익 증가율(12.4%)이 saving rate(3.5%)보다 높습니다.수익 vs 시장: TGRN.F 의 연간 수익(12.4%)이 US 시장(18.9%)보다 느리게 성장할 것으로 예상됩니다.고성장 수익: TGRN.F 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.수익 대 시장: TGRN.F 의 수익(연간 7.8%)이 US 시장(연간 13%)보다 느리게 성장할 것으로 예상됩니다.고성장 매출: TGRN.F 의 수익(연간 7.8%)은 연간 20%보다 느리게 증가할 것으로 예상됩니다.주당순이익 성장 예측향후 자기자본이익률미래 ROE: TGRN.F의 자본 수익률은 3년 후 7.1%로 낮을 것으로 예상됩니다.성장 기업 찾아보기7D1Y7D1Y7D1YPharmaceuticals-biotech 산업의 고성장 기업.View Past Performance기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/06/22 08:59종가2026/05/13 00:00수익2025/12/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Tong Ren Tang Technologies Co. Ltd.는 5명의 분석가가 다루고 있습니다. 이 중 2명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Yanyin ZhuChina International Capital Corporation LimitedZhu ChenCitic Securities Co., Ltd.Jun Zhou LiEverbright Securities Co. Ltd.2명의 분석가 더 보기
공시 • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.
공시 • Apr 27+ 1 more updateTong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2026, at 10:00 China Standard Time. Location: no. 28 tiangui avenue, daxing district, beijing China
공시 • Mar 16Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2025 Results on Mar 27, 2026Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2025 results on Mar 27, 2026
공시 • Feb 06Tong Ren Tang Technologies Co. Ltd. Announces Appointment of Mr. Siu, Paul Yu Hay as Independent Non-Executive Director and Changes in Board Committee Composition, Effective February 6, 2026Tong Ren Tang Technologies Co. Ltd. announced that, following the extraordinary general meeting held on February 6, 2026, announced that, with effect from 6 February 2026, Mr. Siu, Paul Yu Hay has been appointed as an independent non-executive Director of the ninth session of the Board. The resignation of Mr. Li Siu Bun as an independent non-executive Director has also taken effect from the same date. Mr. Siu, Paul Yu Hay will enter into a director's service contract with the Company for a term commencing from the date of his appointment (i.e. 6 February 2026) and until the end of this session of the Board, subject to re-election at the end of the term. The resignation of Mr. Li Siu Bun as the chairman of the Audit Committee and a member of each of the Remuneration Committee and the Strategy and Planning Committee has also taken effect on 6 February 2026. The Board further resolved on 6 February 2026 to appoint Mr. Siu, Paul Yu Hay as the chairman of the Audit Committee, and a member of the Remuneration Committee and the Strategy and Planning Committee, all with effect from the same date.
공시 • Jan 14Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Li Siu Bun from the Positions as an Independent Non-Executive Director, Chairman of the Audit Committee of the Board and A Member of Each of the Remuneration Committee of the Board and the Strategy and Planning CommitteeOn 13 January 2026, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Li Siu Bun, informing the Board of his resignation from the positions as an independent non-executive Director, chairman of the audit committee of the Board and a member of each of the remuneration committee of the Board and the strategy and planning committee of the Board due to work adjustments. The aforesaid resignation of Mr. Li will take effect upon the new independent non-executive Director being elected by the shareholders of the Company at the general meeting to be held in due course.
공시 • Dec 31Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. held an extraordinary general meeting on December 30, 2025, at which the appointment of Ms. Du Xin as a non-executive Director of the ninth session of the Board of the Company was approved and confirmed. The resignation of Mr. Chen Fei as a non-executive Director has also taken effect from the same date. Ms. Du Xin will enter into a director’s service contract with the Company for a term commencing from the date of her appointment, December 30, 2025, and until the end of this session of the Board, subject to re-election at the end of the term. Ms. Du Xin’s remuneration for her services as a non-executive Director is nil, which is determined by the Board with reference to the recommendation from the remuneration committee of the Board, having taken into account her duties and responsibilities with the Company and the prevailing market conditions. As at the date of this announcement, Ms. Du Xin’s biographical details remain unchanged from those stated in the circular dated December 1, 2025 save as disclosed in this announcement. As at the date of this announcement, the Board comprises Mr. Zhang Yi, Mr. Zhang Chun You, and Ms. Wen Kai Ting as executive Directors, Ms. Du Xin and Ms. Feng Li as non-executive Directors, Ms. Chan Ching Har, Eliza, Mr. Zhan Yuan Jing and Mr. Li Siu Bun as independent non-executive Directors, and Mr. Zhu Dong Sheng as employee Director.
공시 • Nov 28+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Executive Changes, Effective November 28, 2025The board of directors (the "Board") of Tong Ren Tang Technologies Co. Ltd. (the "Company") hereby announces that, with effect from 28 November 2025, (i) Mr. Li Yijun ("Mr. Li") has resigned as the company secretary of the Company, the secretary of the Board, and the authorised representative (the "Authorised Representative") under the Rule 3.05 of the Rules Governing the Listing of Securities (the "Listing Rules") on The Stock Exchange of Hong Kong Limited (the "Stock Exchange") of the Company due to his family reasons; and (ii) Ms. Yung Mei Yee ("Ms. Yung") has ceased to serve as the agent for acceptance of service of process and notices on behalf of the Company in Hong Kong under Rule 19A.13(2) of the Listing Rules and Part 16 of the Companies Ordinance (Chapter 622 of the Laws of Hong Kong) (the "Process Agent") due to work adjustment. Both Mr. Li and Ms. Yung have confirmed that they have no disagreement with the Board and there is no matter relating to their resignation that needs to be brought to the attention of the shareholders of the Company or the Stock Exchange. The Board also announced that, with effect from 28 November 2025, (i) Ms. Ma Wing Yee ("Ms. Ma") has been appointed as the company secretary of the Company, the Authorised Representative and the Process Agent; and (ii) Mr. Han Guan Zhao ("Mr. Han") has been appointed as the secretary of the Board. Ms. Ma is an assistant manager of SWCS Corporate Services Group (Hong Kong) Limited and has over 10 years of experience in corporate governance and company secretarial practice in listed companies on the Stock Exchange. She is currently the company secretary or joint company secretary of a few listed companies on the Stock Exchange. Ms. Ma obtained a bachelor's degree in Arts from the University of Hong Kong. She is an associate member of The Hong Kong Chartered Governance Institute and The Chartered Governance Institute in the United Kingdom. Mr. Han, aged 46, is a corporate legal adviser with a postgraduate qualification. He formerly served as the office senior legal affairs manager and manager of the legal affairs department of COFCO Feed Co. Ltd. Mr. Han joined the Company in December 2019, he currently serves as deputy general manager, general legal counsel and chief compliance officer of the Company.
공시 • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2025 Results on Aug 26, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2025 results on Aug 26, 2025
공시 • Jun 12+ 1 more updateTong Ren Tang Technologies Co. Ltd. Approves Final Dividend for the Year Ended 31 December 2024, Payable on 11 August 2025Tong Ren Tang Technologies Co. Ltd. announced at annual general meeting held on June 12, 2025, the shareholders approved the proposal of payment of a final dividend of RMB 0.18 (equivalent to HKD 0.196600) (tax inclusive) per share for the year ended 31 December 2024, will be paid on 11 August 2025 to the Shareholders whose names appear on the registers of members of the Company on 23 June 2025.
공시 • May 20Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2025, at 13:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, beijing, prc., China
공시 • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2024 Results on Mar 28, 2025Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2024 results on Mar 28, 2025
공시 • Oct 29Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Yung Mei Yee as Joint Company SecretaryThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that, due to work adjustment, Ms. Yung Mei Yee ("Ms. Yung") has resigned as the joint company secretary of the Company with effect from 29 October 2024. Ms. Yung has confirmed that she has no disagreement with the Board and there is no matter relating to her resignation that needs to be brought to the attention of the shareholders of the Company or The Stock Exchange of Hong Kong Limited. Following the resignation of Ms. Yung, Mr. Li Yijun, the other Joint Company Secretary, who possess the qualifications and experience of company secretary as required under Rule 3.28 of the Rules Governing the Listing of Securities on the Hong Kong Stock Exchange, will remain in office and act as the sole company secretary of the Company with effect from 29 October 2024.
공시 • Aug 15Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2024 Results on Aug 30, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2024 results on Aug 30, 2024
공시 • Jun 13+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Payment of Final Dividend for the Year Ended 31 December 2023, Payable on 09 August 2024Tong Ren Tang Technologies Co. Ltd. announced that at its AGM held on June 12, 2024, To consider and, if thought fit, to approve the proposal of payment of a final dividend of RMB 0.18 (tax inclusive) per share for the year ended 31 December 2023. Ex-dividend date is 14 June 2024. Record date is 23 June 2024. Payment date is 09 August 2024.
공시 • May 22Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024Tong Ren Tang Technologies Co. Ltd., Annual General Meeting, Jun 12, 2024, at 09:30 China Standard Time. Location: no. 20 nansanhuan zhonglu, fengtai district, the prc, beijing China
공시 • Mar 13Tong Ren Tang Technologies Co. Ltd. to Report Fiscal Year 2023 Results on Mar 22, 2024Tong Ren Tang Technologies Co. Ltd. announced that they will report fiscal year 2023 results on Mar 22, 2024
공시 • Mar 05Tong Ren Tang Technologies Co. Ltd. Receives Notice of Approval for Clinical Trial of MedicineTong Ren Tang Technologies Co. Ltd. announced that the pharmaceutical factory of the Company recently received the Notice of Approval for Clinical Trial of Medicine (Yao Wu Lin Chuang Shi Yan Pi Zhun Tong Zhi Shu) issued by the National Medical Products Administration. Details are as follows: Basic information of the medicine: Qishen Granules (Qi Can Ke Li) Applicant: Tong Ren Tang Technologies Co. Ltd.'s Pharmaceutical Factory. Category of registration: Registration category 1.1 of traditional Chinese medicines. Indications: Benefiting qi and warming yang, and promoting blood circulation and detoxication. Curing for the syndrome of chronic heart failure due to qi deficiency and blood stasis. Acceptance number: CXZL2300074. Notice number: 2024LP00491. Review conclusion: According to the Drug Administration Law of the People's Republic of China (<Zhong Hua Ren Min Gong He Guo Yao Pin Guan Li Fa >) /V Vaccine Administration Law of the People'sRepublic of China (Zhong Hua Ren Minong He Guo Yi Miao Guan Li Fa >) and relevant regulations, Qishen Granules (Qi Can Ke Li) was approved to use in clinical trial for chronic heart failure with reduced ejection fraction. Research and development of the medicine and related information. The Qishen Granules ("Qi Can Ke Li") applied for clinical trial by the pharmaceutical factory of the Company is a traditional Chinese medicine compound preparation, which is applied according to the registration category 1.1 of traditional Chinese medicines and is intended to be used for chronic heart failure syndrome of qi deficiency and bloodstasis. As at the date of this announcement, the Company has invested approximately RMB 7.8 million (unaudited) in the research and development of Qi Can Ke Li). Risk warning: In accordance with the requirements of the relevant laws and regulations on registration of medicine in the PRC, a clinical trial of medicine shall be performed upon receiving the approval for the clinical trial and the medicine shall be produced and marketed only upon being assessed and scrutinized by the National Medical Products Administration. Given its special nature and long cycle from clinical trials to production upon approval which involves many stages, the research and development of medicine are susceptible to many unpredictable factors. There are uncertainties in the progress and results of clinical trials and the future competitive landscape of the pharmaceutical market. Investors are advised to consider the risks involved and be cautious in making investment decisions.
공시 • Jan 30Tong Ren Tang Technologies Co. Ltd. Provides Earnings Guidance for the Twelve Months Ended 31 December 2023Tong Ren Tang Technologies Co. Ltd. provided earnings guidance for the twelve months ended 31 December 2023. For the period the Group is expected to range from a decrease by approximately 3% to an increase by approximately 7% as compared to the corresponding period of last year.
공시 • Jan 22Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesThe board (the "Board") of directors (the "Director(s)") of Tong Ren Tang Technologies Co. Ltd. announce that the extraordinary general meeting of the Company was held on 22 January 2024, approved the appointment of Mr. Di Shu Bing as an executive Director of the eighth session of the Board. Following the resignation of Mr. Gu Hai Ou as an executive Director, Mr. Di Shu Bing has been appointed as an executive Director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Mr. Di Shu Bing commence from the date of appointment (i.e. 22 January 2024) and until the end of this session of the Board, subject to re-elected at the end of the term. Mr. Di Shu Bing will not receive remuneration for his service as an executive Director. The Board announce that the Board resolved on 22 January 2024 to elect Mr. Di Shu Bing as the Chairman of the Board. On the same day, the Board also resolved to appoint Mr. Di Shu Bing as the chairman of the nomination committee of the Board and the chairman of the strategy and planning committee of the Board. The Board hereby announces that, Mr. Di Shu Bing was appointed as an authorized representative of the Company under the Rule 3.05 of the Hong Kong Listing Rules with effect from 22 January 2024.
공시 • Dec 13Tong Ren Tang Technologies Co. Ltd. Announces Resignation of Gu Hai Ou as Executive Director, Chairman of the Board, Chairman of the Nomination Committee, Chairman of the Strategy and Planning CommitteeOn 13 December 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Gu Hai Ou ("Mr. Gu"), informing the Board of his resignation from the positions as an executive Director, chairman of the Board, chairman of the nomination committee of the Board, chairman of the strategy and planning committee of the Board and the authorized representative, due to work adjustments. The above-mentioned resignation of Mr. Gu will take effect upon the new executive Director being elected by the shareholders of the Company (the "Shareholders") at the general meeting to be held. Mr. Gu has confirmed that he has no disagreement with the Board and there is no matter relating to his resignation that needs to be brought to the attention of the Stock Exchange and the Shareholders. The Board further announces on 13 December 2023, proposal in relation to the appointment of Mr. Di Shu Bing ("Mr. Di") as the executive Director of the eighth Board of Directors of the Company, and to have the Board recommend his remuneration and authorize the Board to enter into a service contract with him. The Board therefore proposed to appoint Mr. Di as an executive Director in accordance with relevant laws and regulations and the articles of association of the Company. The proposed appointment of Mr. Di as an executive Director is subject to the approval by the Shareholders at the general meeting. Mr. Di Shu Bing (), aged 49, a senior accountant with a master degree of public administration. Mr. Di previously served as the finance supervisor of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, the deputy manager of Beijing Tong Ren Tang Medicinal Herbal Wine Branch, a member of the Party Committee and the deputy general manager of Beijing Tong Ren Tang Commercial Investment Group, the assistant to the general manager and head of economic operation department of China Beijing Tong Ren Tang Group Co. Ltd., a director of Beijing Tong Ren Tang Health Industry Investment Co. Ltd., the chairman of Beijing Tong Ren Tang Traditional Chinese Medicine Formula Granules Investment Co. Ltd., a director of Beijing Tong Ren Tang Biological Product Development Co. Ltd., a director of Beijing Tong Ren Tang Cosmetics Co. Ltd., the vice chairman of Beijing Entrepreneurs Association and the vice chairman of Beijing Enterprise Confederation, the deputy head of the finance department, the deputy head and head of the investment management department, the secretary of the Party Committee, a director and the general manager of Beijing Tong Ren Tang Company Limited. Mr. Di currently serves as party secretary of the CPC Committee and chairman of Beijing Tong Ren Tang Company Limited, the deputy general manager of China Beijing Tong Ren Tang Group Co. Ltd. and the vice chairman of Beijing Pharmaceutical Profession Association.
공시 • Aug 26Tong Ren Tang Technologies Co. Ltd. Announces Board ChangesTong Ren Tang Technologies Co. Ltd. announced following the resignation of Mr. Wang Yu Wei as an executive director, Mr. Chen Jia Fu has been appointed as an executive director of the eighth session of the board of the company as approved by the Shareholders at the EGM. The terms of office of Mr. Chen Jia Fu commence from the date of appointment (that is 25 August 2023) and until the end of this session of the board, subject to re-elected at the end of the term. Mr. Chen Jia Fu will not receive remuneration for his service as an executive director. Change in board committee members: The board further announced that following the resignation of Mr. Wang Yu Wei as an executive Director, Mr. Chen Jia Fu has been appointed as a member of the strategy and planning committee of the board with effect from 25 August 2023.
공시 • Aug 04Tong Ren Tang Technologies Co. Ltd. to Report First Half, 2023 Results on Aug 24, 2023Tong Ren Tang Technologies Co. Ltd. announced that they will report first half, 2023 results on Aug 24, 2023
공시 • Jun 16+ 1 more updateTong Ren Tang Technologies Co. Ltd. Announces Board ChangesOn 15 June 2023, the board of directors of Tong Ren Tang Technologies Co. Ltd. received a resignation letter from Mr. Wang Yu Wei, informing the Board of Mr. Wang's application for resignation from the position as an executive Director and the general manager of the Company due to work changes. The resignation of Mr. Wang as an executive Director will take effect upon the new executive Director being elected by the shareholders of the Company at the general meeting to be held and his resignation as the General Manager has taken effect from 15 June 2023. The Board further announced that, on 15 June 2023, the Board proposed to appoint Mr. Chen Jia Fu as an executive Director and the General Manager. The proposed appointment of Mr. Chen as an executive Director is subject to the approval by the Shareholders at the general meeting. The proposed appointment of Mr. Chen as the General Manager has taken effect from 15 June 2023. Mr. Chen Jia Fu, aged 54, a pharmacist-in-charge and a licensed pharmacist with a postgraduate degree. He formerly served as the deputy secretary to the Party Committee of the Company, the secretary to the Disciplinary Inspection Committee of the Company, the chairman of the labour committee of the Company, and the deputy general manager of the Company. He used to work as the deputy general manager of Beijing Tong Ren Tang Company Limited and used to work as the chairman of the board, the secretary of general Party branch, the director and the general manager of Beijing Tong Ren Tang Pharmaceutical Co. Ltd. He currently serves as the secretary of the Party Committee of the Company and the General Manager.
공시 • Feb 17Tong Ren Tang Technologies Co. Ltd. Announces Change of DirectorThe board of directors of Tong Ren Tang Technologies Co. Ltd. announced that the extraordinary general meeting (the "EGM") of the Company was held at No. 20 Nansanhuan Zhonglu, Fengtai District, Beijing, the People's Republic of China (the "PRC") at 9:30 a.m., on 16 February 2023 approve the appointment of Ms. Wang Chun Rui as a non-executive Director of the eighth session of the Board of the Company and the remuneration proposed by the Board, and to authorize the Board to enter into the service contract with Ms. Wang Chun Rui. Following the resignation of Ms. Guo Ya Qing as a non-executive director, Ms. Wang Chun Rui has been appointed as a non-executive director of the eighth session of the Board of the Company as approved by the Shareholders at the EGM. The terms of office of Ms. Wang Chun Rui commence from the date of appointment (i.e. 16 February 2023) and until the end of this session of the Board, subject to re-elected at the end of the term. Ms. Wang Chun Rui will not receive remuneration for her service as a non-executive Director.